Mirum Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell MIRM and other ETFs, options, and stocks.

About MIRM

Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The firm focuses on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases. 

CEO
Christopher Peetz
CEOChristopher Peetz
Employees
372
Employees372
Headquarters
Foster City, California
HeadquartersFoster City, California
Founded
2018
Founded2018
Employees
372
Employees372

MIRM Key Statistics

Market cap
5.68B
Market cap5.68B
Price-Earnings ratio
-196.97
Price-Earnings ratio-196.97
Dividend yield
Dividend yield
Average volume
1.22M
Average volume1.22M
High today
$94.89
High today$94.89
Low today
$92.37
Low today$92.37
Open price
$93.64
Open price$93.64
Volume
704.46K
Volume704.46K
52 Week high
$109.28
52 Week high$109.28
52 Week low
$36.88
52 Week low$36.88

Stock Snapshot

As of today, Mirum Pharmaceuticals(MIRM) shares are valued at $94.17. The company's market cap stands at 5.68B, with a P/E ratio of -196.97.

During the trading session on 2026-04-05, Mirum Pharmaceuticals(MIRM) shares reached a daily high of $94.89 and a low of $92.37. At a current price of $94.17, the stock is +1.9% higher than the low and still -0.8% under the high.

Trading activity shows a volume of 704.46K, compared to an average daily volume of 1.22M.

The stock's 52-week range extends from a low of $36.88 to a high of $109.28.

The stock's 52-week range extends from a low of $36.88 to a high of $109.28.

MIRM News

Simply Wall St 23h
Assessing Mirum Pharmaceuticals Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones

Mirum Pharmaceuticals (MIRM) has drawn fresh attention after reporting record quarterly net product revenue, raising full year revenue guidance, achieving its f...

Assessing Mirum Pharmaceuticals Valuation After Record Revenues First GAAP Profitability And Key Trial Milestones
The Motley Fool 4d
Mirum Q2 2025 Earnings Call Transcript

Image source: The Motley Fool. Aug. 6, 2025 at 4:30 p.m. ET CALL PARTICIPANTS Chief Executive Officer — Christopher Peetz President — Peter Radovich Chief Med...

Mirum Q2 2025 Earnings Call Transcript

Analyst ratings

100%

of 11 ratings
Buy
100%
Hold
0%
Sell
0%

People also own

Based on the portfolios of people who own MIRM. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.